

**Table S2. Clinical information regarding 1st and 2nd HSCT in the patient**

First HSCT	Autologous PBSCT and BMT
Conditioning	BU + L-PAM
NCC	PBSCT: $15.6 \times 10^8/\text{kg}$ , BMT: $0.8 \times 10^8/\text{kg}^*$
CD34 <sup>+</sup>	PBSCT: $1.1 \times 10^6/\text{kg}$
Day of neutrophil engraftment (day)	13
Second HSCT	Allogeneic CBT
Conditioning	Flu ( $150 \text{ mg}/\text{m}^2$ ) + L-PAM ( $140 \text{ mg}/\text{m}^2$ ) + TBI 12 Gy
Donor source	Unrelated donor
HLA matching	5/8 (HLA-A, B, C mismatch) Patient: A 02:06/33:03, B 15:18/44:03, C 08:01/14:03, DR:09:01:13:02 Donor: A 02:01/33:03, B 40:01/44:03, C 15:02/14:03, DR 09:01/13:02
NCC	$10.4 \times 10^7/\text{kg}$
CD34 <sup>+</sup>	$2.90 \times 10^5/\text{kg}$
Day of neutrophil engraftment (day)	17
GVHD prophylaxis	FK: $0.03 \text{ mg}/\text{kg}$ (from day -1) + MTX: $7 \text{ mg}/\text{m}^2$ (day +1), $5 \text{ mg}/\text{m}^2$ (day +3, +6)
GVHD	Grade 3 (skin: stage 3, liver: stage 1, gut: stage 2)

\*The patient was unable to obtain sufficient numbers of PBSCs even with 4 rounds of harvest. Therefore, bone marrow was harvested from the patient and added to PBSCs.

Abbreviations: BMT, bone marrow transplantation; BU, busulfan; CBT, cord blood transplantation; FK, tacrolimus; Flu, fludarabine; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; L-PAM, melphalan; MTX, methotrexate; NCC, nuclear cell count; PBSCT, peripheral stem cell transplantation; TBI, total body irradiation